{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:11:13Z","timestamp":1789963873352,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.steroids.2014.06.004","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T12:32:01Z","timestamp":1402489921000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Development of conjugated estrogens\/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss"],"prefix":"10.1016","volume":"90","author":[{"given":"Barry S.","family":"Komm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon N.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2014.06.004_b0005","unstructured":"Duavee [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, A subsidiary of Pfizer Inc.; 2013."},{"key":"10.1016\/j.steroids.2014.06.004_b0455","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 hormone therapy position statement of: The North American Menopause Society","volume":"19","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0015","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0002-9378(13)90437-3","article-title":"Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group","volume":"170","author":"Woodruff","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.steroids.2014.06.004_b0020","first-page":"CD000402","article-title":"Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding","author":"Lethaby","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.steroids.2014.06.004_b0025","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women\u2019s health initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.004_b0030","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.004_b0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women\u2019s Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.steroids.2014.06.004_b0040","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/1933719108325759","article-title":"A new approach to menopausal therapy: the tissue selective estrogen complex","volume":"15","author":"Komm","year":"2008","journal-title":"Reprod Sci"},{"key":"10.1016\/j.steroids.2014.06.004_b0045","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/jcp.24324","article-title":"Evolution of the tissue selective estrogen complex (TSEC)","volume":"228","author":"Komm","year":"2013","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.steroids.2014.06.004_b0050","unstructured":"Boucher M, Archer DF, Pinkerton JV, Kagan R, Ryan KA, Thompson J, et al. Gynecologic safety of bazedoxifene\/conjugated estrogens: pooled analysis of phase 3 trials [poster]. Presented at: 69th Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada; June 11, 2013; Calgary, Alberta, Canada."},{"key":"10.1016\/j.steroids.2014.06.004_b0055","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.steroids.2014.06.004_b0060","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens: a randomized, controlled trial","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifene\/conjugated estrogens for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/13697130903305627","article-title":"Effects of bazedoxifene\/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar\/vaginal atrophy","volume":"13","author":"Bachmann","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.steroids.2014.06.004_b0075","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.steroids.2014.06.004_b0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/13697137.2012.717994","article-title":"Effects of bazedoxifene\/conjugated estrogens on endometrial safety and bone in postmenopausal women","volume":"16","author":"Mirkin","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.steroids.2014.06.004_b0085","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.steroids.2014.06.004_b0090","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/GME.0b013e318271f5e7","article-title":"Breast density changes in a randomized controlled trial evaluating bazedoxifene\/conjugated estrogens","volume":"20","author":"Harvey","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0095","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/AOG.0b013e31828c5974","article-title":"Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial","volume":"121","author":"Pinkerton","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.steroids.2014.06.004_b0100","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex containing bazedoxifene\/conjugated estrogens as a menopausal therapy","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.steroids.2014.06.004_b0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: progress and future perspectives","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.06.004_b0110","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators \u2013 mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.004_b0115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/mol.112.084228","article-title":"Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes","volume":"83","author":"Liu","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.steroids.2014.06.004_b0120","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2174\/1381612023393404","article-title":"SERMs: evolutionary chemistry, revolutionary biology","volume":"8","author":"Miller","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.steroids.2014.06.004_b0125","first-page":"5683","article-title":"Selective estrogen receptor modulation: a personal perspective","volume":"61","author":"Jordan","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2014.06.004_b0130","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.004_b0135","first-page":"253","article-title":"Tamoxifen, raloxifene, and the prevention of breast cancer","volume":"20","author":"Jordan","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.steroids.2014.06.004_b0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jbmr.191","article-title":"Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women","volume":"26","author":"Cummings","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.steroids.2014.06.004_b0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-012-2041-5","article-title":"Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene","volume":"134","author":"Powles","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.06.004_b0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.06.004_b0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.004_b0160","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.004_b0165","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0170","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.004_b0175","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.004_b0180","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0140-6736(94)92466-X","article-title":"Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial","volume":"343","author":"Kedar","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.06.004_b0185","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/gme.0b013e3181a816be","article-title":"Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0190","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","article-title":"Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women","volume":"105","author":"Ronkin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.steroids.2014.06.004_b0195","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.06.004_b0200","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.111.072249","article-title":"The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1","volume":"80","author":"Lewis-Wambi","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.steroids.2014.06.004_b0205","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women","volume":"16","author":"Archer","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2474-11-130","article-title":"Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis","volume":"11","author":"Christiansen","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.steroids.2014.06.004_b0215","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.steroids.2014.06.004_b0220","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.steroids.2014.06.004_b0225","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1021\/jm010086m","article-title":"Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens","volume":"44","author":"Miller","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.steroids.2014.06.004_b0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mce.2008.01.027","article-title":"Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland","volume":"287","author":"Crabtree","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.steroids.2014.06.004_b0235","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/en.2008-1210","article-title":"Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland","volume":"150","author":"Peano","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.06.004_b0240","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1078-0432.CCR-12-3771","article-title":"Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease","volume":"19","author":"Wardell","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2014.06.004_b0245","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/GME.0b013e31827ce57a","article-title":"Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model","volume":"20","author":"Ethun","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0250","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/GME.0b013e318252e46d","article-title":"Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys","volume":"19","author":"Ethun","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0255","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1210\/en.2010-1010","article-title":"Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model","volume":"152","author":"Kulak","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.06.004_b0260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/me.2008-0366","article-title":"Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination","volume":"23","author":"Berrodin","year":"2009","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.steroids.2014.06.004_b0265","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jsbmb.2009.11.003","article-title":"Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens","volume":"118","author":"Chang","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.06.004_b0270","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bone.2011.05.024","article-title":"Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats","volume":"49","author":"Komm","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.steroids.2014.06.004_b0275","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1210\/en.2008-0817","article-title":"The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention","volume":"149","author":"Kharode","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.06.004_b0280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1933719111431002","article-title":"Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation","volume":"20","author":"Oliva","year":"2013","journal-title":"Reprod Sci"},{"key":"10.1016\/j.steroids.2014.06.004_b0285","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1210\/en.2012-1583","article-title":"Effects of the conjugated equine estrogen\/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice","volume":"153","author":"Song","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.06.004_b0290","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/en.2012-2038","article-title":"Inhibitory effects of a bazedoxifene\/conjugated equine estrogen combination on human breast cancer cells in vitro","volume":"154","author":"Song","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.06.004_b0295","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0b013e318031a83d","article-title":"The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety","volume":"14","author":"Stovall","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0300","unstructured":"Evista (LY139481) Clinical Study Results. Lilly Clinical Trials Registry. Available at: http:\/\/www.lillytrials.com\/results\/Evista.pdf. Accessed February 5, 2014."},{"key":"10.1016\/j.steroids.2014.06.004_b0305","unstructured":"Guidance for Industry. Estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms \u2013 recommendations for clinical evaluation. Food and Drug Administration. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071643.pdf. Accessed January 6, 2014."},{"key":"10.1016\/j.steroids.2014.06.004_b0310","first-page":"93","article-title":"Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses","volume":"52","author":"Carranza-Lira","year":"2007","journal-title":"Int J Fertil Womens Med"},{"key":"10.1016\/j.steroids.2014.06.004_b0315","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.fertnstert.2006.07.236","article-title":"Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies [abstract O-206]","volume":"86","author":"Van Duren","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.steroids.2014.06.004_b0320","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0015-0282(01)01791-5","article-title":"Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate","volume":"75","author":"Utian","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.steroids.2014.06.004_b0325","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1200\/JCO.2008.21.7166","article-title":"Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women\u2019s health initiative randomized trial","volume":"27","author":"McTiernan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.06.004_b0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/93.1.51","article-title":"Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo","volume":"93","author":"Freedman","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.004_b0335","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2013.06.008","article-title":"Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study","volume":"76","author":"Palacios","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.06.004_b0340","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S1470-2045(05)70390-9","article-title":"Mammographic breast density as an intermediate phenotype for breast cancer","volume":"6","author":"Boyd","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.steroids.2014.06.004_b0345","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1055-9965.EPI-06-0034","article-title":"Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis","volume":"15","author":"McCormack","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.steroids.2014.06.004_b0350","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10549-011-1803-9","article-title":"Breast tenderness after initiation of conjugated equine estrogens and mammographic density change","volume":"131","author":"Crandall","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.06.004_b0355","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-011-1848-9","article-title":"Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women\u2019s health initiative clinical trials","volume":"132","author":"Crandall","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.06.004_b0360","unstructured":"Pickar J, Ryan K, Messig M, Komm B, Mirkin S. Breast safety of bazedoxifene\/conjugated estrogens: pooled analysis of phase 3 trials [abstract]. Presented at: Annual Meeting of the North American Menopause Society; October 9\u201312, 2013; Grapevine, TX."},{"key":"10.1016\/j.steroids.2014.06.004_b0365","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.maturitas.2007.09.006","article-title":"Healthcare seeking and treatment for menopausal symptoms in the United States","volume":"58","author":"Williams","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.06.004_b0370","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/jwh.2013.4392","article-title":"Evaluation of the efficacy and safety of bazedoxifene\/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause And Response to Therapy (SMART) Trials","volume":"23","author":"Pinkerton","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.steroids.2014.06.004_b0375","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1477-7525-3-47","article-title":"Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review","volume":"3","author":"Utian","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.steroids.2014.06.004_b0380","unstructured":"Abraham L, Messig M, Pinkerton JV, Mirkin S, Ryan K. Menopause-specific quality of life with bazedoxifene\/conjugated estrogens [abstract]. Presented at: Annual Meeting of the North American Menopause Society; October 9\u201312, 2013; Grapevine, TX."},{"key":"10.1016\/j.steroids.2014.06.004_b0385","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/GME.0b013e31829f0433","article-title":"Sleep parameters and health-related quality of life with bazedoxifene\/conjugated estrogens: a randomized trial","volume":"21","author":"Pinkerton","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0390","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.maturitas.2009.06.006","article-title":"Bazedoxifene\/conjugated estrogens and quality of life in postmenopausal women","volume":"63","author":"Utian","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.06.004_b0395","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0378-5122(96)01038-9","article-title":"A menopause-specific quality of life questionnaire: development and psychometric properties","volume":"24","author":"Hilditch","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.06.004_b0400","first-page":"351","article-title":"A prospective population-based study of menopausal symptoms","volume":"96","author":"Dennerstein","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.steroids.2014.06.004_b0405","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1016\/S0002-9378(98)70555-1","article-title":"Urogenital aging\u2013a hidden problem","volume":"178","author":"Samsioe","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.steroids.2014.06.004_b0460","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society","volume":"17","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.06.004_b0420","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.004_b0425","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women\u2019s health initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.steroids.2014.06.004_b0430","unstructured":"Summary of Product Characteristics. Conbriza. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000913\/WC500033577.pdf. Accessed December 19, 2013."},{"key":"10.1016\/j.steroids.2014.06.004_b0435","unstructured":"Skouby SO, Lobo RA, Ryan KA, et al. Low risk of thrombophilia with bazedoxifene\/conjugated estrogens: summary of pooled coagulation data from the selective estrogens, menopause, and response to therapy trials [abstract]. Presented at: Annual Meeting of the Endocrine Society; June 23\u201326, 2012; Houston, TX."},{"key":"10.1016\/j.steroids.2014.06.004_b0440","unstructured":"Pickar JH, Lobo R, Ebede B, Thompson J, Mirkin S. Pooled cardiovascular safety results from phase 3 trials of bazedoxifene\/conjugated estrogens [abstract]. Presented at: Annual Meeting of the North American Menopause Society; October 3\u20136, 2012; Kissimmee, FL."},{"key":"10.1016\/j.steroids.2014.06.004_b0445","first-page":"SAT-30","article-title":"A pooled analysis of the effects of bazedoxifene\/conjugated estrogens on lipid parameters from the selective estrogens, menopause, and response to therapy trials [abstract]","volume":"33","author":"Mirkin","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.steroids.2014.06.004_b0450","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","article-title":"Bazedoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women","volume":"92","author":"Archer","year":"2009","journal-title":"Fertil Steril"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:02:23Z","timestamp":1758535343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X14001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":90,"alternative-id":["S0039128X14001433"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2014.06.004","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of conjugated estrogens\/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2014.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}